Description:
Allogeneic hematopoietic stem cell transplantation is a life-saving procedure in patients
with blood cancers. Cord blood (CB) represents an alternative source of stem cells, which is
associated with a lower risk of relapse, especially in the presence of minimal residual
disease in the setting of acute leukemia and myelodysplasia. Furthermore, CB has the added
advantage of being associated with a low risk of chronic graft versus host disease (GVHD).
Unfortunately, CB transplants are hampered by a higher risk of transplant related mortality
(TRM) when compared to bone marrow/peripheral blood transplants because of the limited cell
dose of CB.
In the previous UM171 trial (NCT02668315), the CB expansion protocol using the ECT-001-CB
technology (UM171 molecule) has proven to be technically feasible and safe. UM171 expanded CB
was associated with a median neutrophil recovery at day (D)+18 post transplant. Amongst 22
patients who received a single UM171 CB transplant with a median follow-up of 18 months, risk
of TRM (5%) and grade 3-4 acute GVHD (10%) were low. There was no moderate-severe chronic
GVHD. Thus, overall and progression free survival at 12 months were impressive at 90% and
74%, respectively. The UM171 expansion protocol allowed access to smaller, better HLA matched
CBs as >80% of patients received a 6-7/8 HLA matched CB. Interestingly there were 5 patients
who had already failed an allogeneic transplant and 5 patients with refractory/relapsed acute
leukemia/aggressive lymphoma. Despite this high risk population, progression was 20% at 12
months. Hence, in this new trial, investigators are targeting patients with high and very
high-risk acute leukemia/myelodysplasia to test the antileukemia effect of this new graft, a
UM171 expanded CB.
Title
- Brief Title: UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia
- Official Title: A Phase II Open-label Study of ECT-001-expanded Cord Blood Transplantation in Patients With High-risk Acute Leukemia/Myelodysplasia
Clinical Trial IDs
- ORG STUDY ID:
ECT-001-CB.002
- NCT ID:
NCT03913026
Conditions
- High Risk Hematologic Malignancy
- Cord Blood Transplant
Interventions
Drug | Synonyms | Arms |
---|
Transplant with an expanded ECT-001 cord blood | | Main intervention |
Purpose
Allogeneic hematopoietic stem cell transplantation is a life-saving procedure in patients
with blood cancers. Cord blood (CB) represents an alternative source of stem cells, which is
associated with a lower risk of relapse, especially in the presence of minimal residual
disease in the setting of acute leukemia and myelodysplasia. Furthermore, CB has the added
advantage of being associated with a low risk of chronic graft versus host disease (GVHD).
Unfortunately, CB transplants are hampered by a higher risk of transplant related mortality
(TRM) when compared to bone marrow/peripheral blood transplants because of the limited cell
dose of CB.
In the previous UM171 trial (NCT02668315), the CB expansion protocol using the ECT-001-CB
technology (UM171 molecule) has proven to be technically feasible and safe. UM171 expanded CB
was associated with a median neutrophil recovery at day (D)+18 post transplant. Amongst 22
patients who received a single UM171 CB transplant with a median follow-up of 18 months, risk
of TRM (5%) and grade 3-4 acute GVHD (10%) were low. There was no moderate-severe chronic
GVHD. Thus, overall and progression free survival at 12 months were impressive at 90% and
74%, respectively. The UM171 expansion protocol allowed access to smaller, better HLA matched
CBs as >80% of patients received a 6-7/8 HLA matched CB. Interestingly there were 5 patients
who had already failed an allogeneic transplant and 5 patients with refractory/relapsed acute
leukemia/aggressive lymphoma. Despite this high risk population, progression was 20% at 12
months. Hence, in this new trial, investigators are targeting patients with high and very
high-risk acute leukemia/myelodysplasia to test the antileukemia effect of this new graft, a
UM171 expanded CB.
Detailed Description
Methodology:
This is a multi-center open label phase II clinical trial. Patients with high and very
high-risk acute leukemia/myelodysplasia will receive a single 5-7/8 HLA matched ECT-001
(UM171) expanded cord blood after an ablative conditioning regimen. This group of patients
would be expected to have poor progression free survival (PFS) after a conventional
allogeneic transplant (bone marrow-peripheral blood).
Investigators key primary and secondary objectives include:
1. To confirm low Transplant Related Mortality (TRM)
2. To evaluate relapse free survival (RFS)
3. To analyze kinetics of hematologic engraftment;
4. To evaluate the incidence of acute and chronic GVHD
5. To evaluate the safety of the procedure
6. To evaluate incidence of infectious complications
7. To analyze duration of hospitalization
8. To evaluate the incidence of pre-engraftment/engraftment syndrome (PES/ES)
9. To analyze the effect of cryopreservation of the expanded CD34+ fraction on safety and
efficacy endpoints
Trial Arms
Name | Type | Description | Interventions |
---|
Main intervention | Experimental | Eligible patients will receive an ablative conditioning regimen and be infused with an ECT-001 expanded cord-blood. The ECT-001 expanded CB could be infused fresh, or cryopreserved. | - Transplant with an expanded ECT-001 cord blood
|
Eligibility Criteria
Inclusion Criteria:
1. Presence of high-risk acute leukemia/myelodysplasia defined as one of the following:
I. Acute Myeloid Leukemia:
1. Primary induction failure (no CR or CRi after ≥ 2 courses of induction therapy or
after ≥ 1 induction containing high dose Ara-C)
2. Chemorefractory relapse (no CR or CRi after 1 chemointensive treatment)
3. Relapse after allogeneic or autologous transplant
4. High risk AML in CR1: i) any adverse genetic abnormality as defined by European
Leukemia Net excluding FLT3 mutation; ii) secondary or therapy related AML
excluding good risk genetic abnormalities (as defined by ELN); or iii) any other
poor risk feature known to be associated with a PFS or DFS ≤40% at 2 years after
conventional transplantation.
5. CR2 excluding good risk genetic abnormalities defined by ELN
6. ≥CR3
II. Acute Lymphoid Leukemia
1. Primary induction failure (≥ 2 inductions)
2. Chemorefractory relapse (at least 1 intensive induction chemotherapy;
blinatumomab, inotuzumab or CAR-T cells may be considered as an equivalent)
3. Relapse after allogeneic or autologous transplant
4. High risk ALL in CR1: Ph like ALL or any other poor risk feature known to be
associated with an PFS or DFS ≤40% at 2 years after conventional transplantation.
5. ≥CR2
6. MRD+ within 1 month of start of conditioning regimen.
III. Myelodysplastic syndrome
1. Relapse after allogeneic or autologous transplant
2. ≥10 % blasts within 1 month of start of conditioning regimen
3. Very poor cytogenetics (>3 abnormalities)
4. Any poor risk feature known to be associated with a PFS or DFS ≤40% at 2 years
after conventional transplantation
5. TP53 mutation
6. ≥40 years old and RAS or JAK2 mutation
7. CMML with HCT-specific CPSS score high or intermediate-2
8. Stable disease (absence of CR/PR/HI) after 6 cycles of azacitidine (or another
demethylating agent)
9. Progressive disease while on azacitidine (or another demethylating agent)
2. 18-70 years old
3. Availability of 2 CBs ≥ 4/8 HLA match when A, B, C and DRB1 are performed at the
allele level.
I. Cord to be expanded:
1. CD34+ cell count >0.5 x 105/kg and TNC>1.5 x 107/kg (these numbers are all
pre-freeze)
2. Needs to be erythrodepleted by bank prior to cryopreservation
3. Must come from a cord bank that is FACT (Foundation for the Accreditation of
Cellular Therapy) accredited, FDA approved or eligible for NMDP IND.
II. Non-expanded CB/back-up cord:
1. Pre-freeze TNC count ≥ 2.0 x 107/kg with CD34+ cells ≥1.5 x 105/kg or TNC count ≥
1.5 x 107 TNC/kg with CD34+ cells ≥1.7 x 105/kg. If a single cord does not meet
these criteria, 2 back up cords will be an acceptable alternative with a minimum
for each of 1.5 x 107/kg TNC and 1 x 105/kg CD34+ cells; another acceptable HSC
back up source could be a haploidentical donor with medical clearance prior to
starting conditioning regimen.
2. Must come from a cord bank that is FACT accredited, FDA approved or eligible for
NMDP IND
4. Karnofsky score ≥ 70%
5. Bilirubin < 2 x upper limit of normal (ULN) unless felt to be related to Gilbert's
disease or hemolysis; AST and ALT ≤ 2.5 x ULN; alkaline phosphatase ≤ 5 x ULN.
6. Estimated or measured creatinine clearance ≥ 60 ml/min/1.73m2.
7. Hematopoietic cell transplantation specific comorbidity index (HCT-CI) ≤5 for patients
< 60 years old; HCT-CI ≤3 for patients < 60 years old and acute leukemia not in
CR/CRi; HCT-CI ≤3 for patients 60-65 years old; HCT-CI ≤1 if 66-70 years old.
8. Left ventricular ejection fraction ≥ 40%
9. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and diffusing
capacity corrected for hemoglobin (DLCOc) ≥ 50% of predicted
10. Signed written informed consent
11. Female patients of childbearing potential must have a negative serum pregnancy test
within 7 days of enrolment and must be willing to use an effective contraceptive
method while enrolled in the study.
Exclusion Criteria:
1. Patient never treated with cytotoxic chemotherapy and planned conditioning regimen
does not include 12 Gy TBI (exceptions allowed if approved by PI).
2. Allogeneic myeloablative transplant within 6 months.
3. Autologous hematopoietic stem cell transplant within 6 months.
4. Planned use of ATG in conditioning regimen (exceptions allowed if approved by PI in
which case ATG must be adjusted for weight/lymphocyte count and given more than 1 week
prior to transplant; any patient who receives ATG will have immune recovery studies
but will not be counted with rest of patients and will be analyzed separately).
5. Planned use of an HLA matched CB (8/8 allele matched)
6. Uncontrolled infection.
7. Presence of a malignancy other than the one for which the CB transplant is being
performed, with an expected survival estimated to be less than 75% at 5 years.
8. Seropositivity for HIV.
9. Hepatitis B or C infection with measurable viral load. Patients with chronic hepatitis
B or C infection regardless of viral load require clear documentation of absence of
cirrhosis by either fibroscan or biopsy. If fibroscan is the method used, the test
must be unequivocally negative.
10. Liver cirrhosis.
11. Active central nervous system involvement
12. Chloroma > 2 cm
13. ≥50% blasts in marrow in an evaluable marrow sample (>25% of normal cellularity for
age) collected less than one month prior to start of conditioning regimen.
14. Peripheral blasts >1000/mm3
15. Pregnancy, breastfeeding or unwillingness to use appropriate contraception.
16. Participation in a trial with an investigational agent within 30 days prior to entry
in the study.
17. Patient unable to give informed consent or unable to comply with the treatment
protocol including appropriate supportive care, follow-up, and tests.
18. Any abnormal condition or laboratory result that is considered by the PI capable of
altering patient's condition or study outcome.
Maximum Eligible Age: | 70 Years |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Transplant Related Mortality (TRM) |
Time Frame: | 1 year |
Safety Issue: | |
Description: | TRM is defined as any death of any cause other than malignant relapse, occurring after the commencement of conditioning regimen that could be related to the transplantation procedure. |
Secondary Outcome Measures
Measure: | Neutrophil Engraftment |
Time Frame: | 42 days |
Safety Issue: | |
Description: | Time to neutrophil engraftment is defined as the first day of attainment of an absolute neutrophil count (ANC) ≥0.5 x 109/L for 3 consecutive days. Time to ANC ≥ 0.1 x 109/L will also be documented as it seems to predict TRM. |
Measure: | Graft failure |
Time Frame: | 42 days |
Safety Issue: | |
Description: | Absence of neutrophil engraftment by day 42 or secondary graft failure without any obvious cause. |
Measure: | Platelet Engraftment |
Time Frame: | 60 days |
Safety Issue: | |
Description: | Platelet engraftment is defined as the first day of a sustained platelet count ≥ 20 x 109/L with no platelet transfusion in the preceding 7 days as per CIBMTR standards (www.cibmtr.org). |
Measure: | Incidence of Acute Graft Versus Host Disease (aGVHD) |
Time Frame: | 1 year |
Safety Issue: | |
Description: | The time to onset and maximal grade will be recorded. Acute GVHD will be defined as classic acute (time of onset of symptoms ≤ 100 days) or persistent, recurrent, or late onset acute GVHD (time of onset of symptoms > 100 days) as defined by the NIH. Results will be compared to patients at the same institution transplanted with different stem cell sources. |
Measure: | Incidence of Chronic Graft Versus Host Disease (cGVHD) |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Defined as per NIH global severity scores for mild, moderate, and severe chronic GVHD. |
Measure: | Adverse events grade 3 or higher |
Time Frame: | 3 years |
Safety Issue: | |
Description: | All adverse events occurring during the clinical trial, including the protocol-defined post-treatment follow-up period, qualifying as a grade ≥ 3 toxicity per the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. |
Measure: | Incidence of severe infectious complications. |
Time Frame: | 3 years |
Safety Issue: | |
Description: | Any of the following infections requiring systemic therapy will be captured: invasive candidiasis, aspergillus, other invasive fungi, CMV, adenovirus, EBV, HHV-6, HSV, VZV, PCP, toxoplasmosis and mycobacterium. |
Measure: | Hospitalization events |
Time Frame: | 1 year |
Safety Issue: | |
Description: | Total number of days admitted to the hospital in the first 100 days following transplant. Last day of fever (≥38.0°C) prior to engraftment, and number of days of parenteral feeding during transplant admission. |
Measure: | Incidence of preengraftment/engraftment syndrome (ES) requiring therapy. |
Time Frame: | 30 days |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Ciusss de L'Est de l'Île de Montréal |
Trial Keywords
Last Updated
August 9, 2021